RTW Investments LP Sells 6,273,790 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

RTW Investments LP reduced its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 42.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 8,672,630 shares of the company’s stock after selling 6,273,790 shares during the period. RTW Investments LP’s holdings in Taysha Gene Therapies were worth $15,004,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hsbc Holdings PLC increased its holdings in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after purchasing an additional 8,076 shares in the last quarter. Virtus ETF Advisers LLC increased its holdings in Taysha Gene Therapies by 43.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 31,597 shares of the company’s stock worth $55,000 after purchasing an additional 9,494 shares in the last quarter. Geode Capital Management LLC increased its holdings in Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after purchasing an additional 9,591 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after purchasing an additional 11,390 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in Taysha Gene Therapies by 32.3% during the 4th quarter. ProShare Advisors LLC now owns 59,076 shares of the company’s stock worth $102,000 after purchasing an additional 14,418 shares in the last quarter. 77.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $6.43.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $2.56 on Friday. The stock has a fifty day simple moving average of $1.70 and a two-hundred day simple moving average of $1.82. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $4.32. The firm has a market cap of $524.94 million, a price-to-earnings ratio of 4.06 and a beta of 0.90. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.30 million during the quarter, compared to analyst estimates of $1.48 million. During the same period in the prior year, the company earned ($0.10) earnings per share. Analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.